Clara Daschner

Clara Daschner

Auto-generated profile, based on publicly available information

Clara Daschner

Department of Nephrology, Endocrinology, Hypertensiology and Rheumatology, University Hospital Mannheim, University of Heidelberg, Mannheim, Germany

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2024 in American Journal of Hypertension
Verified
Journal Article
Closed access
CDClara Daschner
Clara Daschner
MKMarcus E. Kleber
Marcus E. Kleber
NANiklas Ayasse
Niklas Ayasse
KSKsenija Stach
Ksenija Stach
GYGökhan Yücel
Gökhan Yücel
BYBabak Yazdani
Babak Yazdani
BACKGROUND: Arterial hypertension is a significant risk factor for cardiovascular (CV) morbidity and mortality. Although central blood pressure (BP) evaluation is considered the gold standard, the reliability of non-invasive measurements remains unclear. Therefore, we compared the predictive value of invasively measured central BP with non-invasively measured brachial BP and analyzed pulse pressure (PP) amplification (delta-PP; the difference between central and peripheral PP) as an independent predictor of mortality. METHODS: We analyzed systolic BP (SBP), diastolic BP (DBP), mean arterial BP (MAP), PP, and delta-PP as predictors of CV and all-cause mortality in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study, involving 3,316 patients referred for coronary angiography. RESULTS: All brachial BP parameters, except DBP, were significantly linked to all-cause and CV mortality in a univariate analysis. A 10 mm Hg increase in SBP, MAP, and PP corresponded to increased risks of all-cause (11%, 10%, and 19%) and CV mortality (11%, 11%, and 18%). Central SBP and PP showed similar, but numerically weaker, associations with increased risks of all-cause (5% and 10%) and CV mortality (4% and 8%). After adjusting for age, sex, body mass index, diabetes mellitus, and eGFR, only delta-PP independently predicted mortality with a 10 mm Hg increase linked to a 4% reduction in all causes and a 6% reduction in CV mortality. CONCLUSIONS: Neither brachial nor centrally measured BP parameters were independent mortality predictors in contrast to PP amplification, which remained an independent predictor of mortality in multivariate analysis, in a cohort with a medium to high CV risk profile. As PP amplification decreased, mortality increased.

16 December 2025 in Clinical Chemistry
Verified
Journal Article
Closed access
CDClara Daschner
Clara Daschner
MKMarcus E Kleber
Marcus E Kleber
ABAnders H Berg
Anders H Berg
FHFaeq Husain-Syed
Faeq Husain-Syed
JSJürgen E Scherberich
Jürgen E Scherberich
BYBabak Yazdani
Babak Yazdani
Background: Serum uromodulin (SUmod) and carbamylated albumin (C-Alb) are emerging biomarkers for chronic kidney disease (CKD) progression and mortality. SUmod reflects tubular health, while C-Alb is associated with excretory kidney function, CKD progression, and cardiovascular (CV) mortality. We hypothesized that the combined use of these markers would improve mortality risk assessments. Methods: We analyzed the associations of C-Alb and SUmod levels with the estimated glomerular filtration rate (eGFR) along with their combined predictive value for assessing mortality in 3316 participants of the Ludwigshafen Risk and Cardiovascular Health study showing mid to high CV risk. Results: SUmod correlated moderately with eGFR (ρ = 0.39, P < 0.001) and weakly and inversely with C-Alb (ρ = −0.19, P < 0.001); C-Alb negatively correlated with eGFR (ρ = −0.38, P < 0.001). Patients in the C-Alb high/SUmod low group had the highest mortality risk [hazard ratio (HR)= 3.30; 95% CI, 2.73–3.99], which remained significant after adjustment for confounders, including eGFR (HR = 1.89; 95% CI, 1.24–1.89). In risk-prediction models for all-cause mortality, adding SUmod increased the area under the curve (AUC) from 0.728 to 0.746 (P < 0.001), C-Alb to 0.738 (P = 0.026), and both combined to 0.751 (P < 0.001). For CV mortality, AUC rose from 0.698 to 0.721 with SUmod (P < 0.001), to 0.711 with C-Alb (P = 0.018), and to 0.727 (P = 0.004) in the combined model. Conclusions: SUmod and C-Alb levels yield complementary insights into kidney function, biology, and mortality risk beyond eGFR. Low SUmod/high C-Alb revealed the highest mortality risk, even after multivariate adjustment. German Clinical Trials Register Number: DRKS00032641.

30 January 2026 in Kidney360
Verified
Journal Article
Open access
DKDavid Klank
David Klank
JFJulian Friedrich
Julian Friedrich
LRLina Zoe Rüsing
Lina Zoe Rüsing
CDClara Daschner
Clara Daschner
SPStefan Porubsky
Stefan Porubsky
Raoul BergnerRaoul Bergner
Raoul Bergner
Key Points: Kidney involvement in patients with multiple myeloma has many different findings in kidney histology. Persistent dialysis requirement is a major cause of mortality. The rapid initiation of modern myeloma therapy is essential to prevent the need for dialysis and reduce mortality. Background: Acute or CKD affects 20%–40% of patients with multiple myeloma (MM). While the negative prognostic effect of kidney involvement is established, the specific effect of different histological patterns remains poorly understood. We aimed to characterize the clinical outcomes associated with distinct kidney histologies in patients with MM. Methods: We retrospectively analyzed 193 patients with MM who underwent kidney biopsy, comparing outcomes with 62 patients with MM without kidney disease. Patients were categorized by histological findings: cast nephropathy (CN, n =120), lightchain (AL) amyloidosis ( n =19), monoclonal Ig deposition disease (MIDD, n =8), and other renal disease ( n =46). We evaluated kidney function, dialysis requirements, treatment responses, and survival across histological subtypes and treatment modalities (conventional therapy versus modern agents including proteasome inhibitors, CD38 antibodies, and autologous stem cell transplantation). Results: The CN and MIDD groups had the lowest median eGFR at biopsy (13.0 and 25.5 ml/min per 1.73 m 2 , respectively). Nephrotic-range proteinuria (>3.5 g/24 hours per Kidney Disease Improving Global Outcomes) was observed in the AL amyloidosis group (median 3910 mg/24 hours). KRT was initiated in 42.5% of patients. The proportion achieving KRT independence was 42.4% in the CN group and 50% in the other renal disease group, whereas none in the AL amyloidosis or MIDD groups recovered sufficient native kidney function. Modern combination therapy significantly improved renal outcomes, with 100% of patients receiving triple therapy showing renal response. KRT dependency was the strongest predictor of mortality: Patients remaining on KRT had significantly shorter survival compared with those never requiring KRT (12.7 versus 56.2 months, P < 0.001). The extent of improvement in kidney function did not influence survival; only dialysis status was prognostically relevant. Conclusions: Kidney histology determines distinct clinical trajectories in patients with MM, with CN showing potential for dialysis reversibility. Modern combination therapies significantly improve renal outcomes. The requirement for ongoing KRT was the primary predictor of overall survival.